中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 7
Jul.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(7): 1509-1512

Analysis of the results of hepatitis C antibody screening in 2020 in Yanbian area of China

DOI: 10.3969/j.issn.1001-5256.2022.07.011
  • 1.

    Department of Infectious Diseases, The Affiliated Hospital of Yanbian University, Yanji, Jilin 133002, China

  • 2.

    China Liver Health, Beijing 100071, China

Research funding:

Zhonglian Liver Health Promotion Center- Public Welfare Project for the Elimination of Hepatitis C (20170903);

National Natural Science Foundation of China (81360075);

Jilin Provincial Health Science and Technology Capacity Enhancement Project (2021LC077)

More Information
  • Corresponding author: PIAO Hongxin, 15526770394@163.com(ORCID: 0000-0002-3294-9937); YANG Enyue, enyueyang@163.com(ORCID: 0000-0002-2323-4526)
  • Received Date: 2021-12-02
  • Accepted Date: 2022-01-29
  • Published Date: 2022-07-20
    Abstract
  •   Objective  To investigate the influencing factors for hepatitis C antibody and the preventive effect of hepatitis C in Yanbian Prefecture of China in the recent 7 years.  Methods  A total of 1184 residents in Yanbian were randomly selected in 2020, peripheral blood samples were collected, and the colloidal gold method was used to detect hepatitis C antibody. The positive rate of hepatitis C antibody in 2020 was compared with the data in 2013. The chi-square test or the Fisher's exact test was used for comparison of categorical data between groups, and then pairwise comparison was performed.  Results  The positive rate of hepatitis C antibody in Yanbian residents screened in 2020 was significantly lower than that in 2013 (6.42% vs 10.60%, χ2=11.212, P=0.001). The Fisher's exact test (2×C) was performed for the positive rate of hepatitis C antibody between different age groups in 2020, and the results showed that there was a significant difference between the 5 age groups (χ2=29.478, P < 0.001). Pairwise comparison after Bonferroni adjustment showed that there was a significant difference between the≥60 years group and the 50-59 years group, between the≥60 years group and the 40-49 years group, and between the≥60 years group and the 30-39 years group (χ2=11.268, 14.804, and 9.293, all P < 0.01), while there was no significant difference between the other groups (P > 0.01). The Chinese Korean population had a significantly higher positive rate of antibody than the non-Chinese Korean population (10.45% vs 5.50%, χ2=7.236, P=0.007). As for the farmers, the positive rate of hepatitis C antibody in 2020 was significantly lower than that in 2013 (7.16% vs 19.74%, χ2=36.604, P < 0.001). The positive rate of hepatitis C antibody in rural areas was significantly higher than that in urban areas (7.33% vs 4.26%, χ2=3.882, P=0.049).  Conclusion  The positive rate of hepatitis C antibody is mainly associated with age, nationality, occupation, and region. There is a reduction in the positive rate of hepatitis C antibody in Yanbian in the recent 7 years, suggesting that Yanbian Prefecture has achieved a marked effect in the prevention and treatment of hepatitis C.

     

    • FullText(HTML)
  • loading
    • References(23)
  • [1]
    PIETSCHMANN T, BROWN R. Hepatitis C virus[J]. Trends Microbiol, 2019, 27(4): 379-380. DOI: 10.1016/j.tim.2019.01.001.
    [2]
    THOMAS DL. Global control of hepatitis C: where challenge meets opportunity[J]. Nat Med, 2013, 19(7): 850-858. DOI: 10.1038/nm.3184.
    [3]
    Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study[J]. Lancet Gastroenterol Hepatol, 2017, 2(3): 161-176. DOI: 10.1016/S2468-1253(16)30181-9.
    [4]
    SUN HQ, XIAO GX, GUO Y, et al. Spatial clustering and changing trend of hepatitis C prevalence during 2008-2012 in China[J]. China Public Health, 2014, 30(3): 286-289. DOI: 10.11847/zgggws2014-30-03-10.

    孙海泉, 肖革新, 郭莹, 等. 中国2008—2012年丙肝流行规律及空间聚集性分析[J]. 中国公共卫生, 2014, 30(3): 286-289. DOI: 10.11847/zgggws2014-30-03-10.
    [5]
    LU XR, ZHAO QL. Epidemiological characteristics of viral hepatitis C in Jilin Province, 2008-2017[J]. Pract Prevent Med, 2019, 26(7): 805-807. DOI: 10.3969/j.issn.1006-3110.2019.07.009.

    卢欣荣, 赵庆龙. 2008-2017年吉林省丙型病毒性肝炎流行病学特征[J]. 实用预防医学, 2019, 26(7): 805-807. DOI: 10.3969/j.issn.1006-3110.2019.07.009.
    [6]
    Chinese Society of Hepatology, Chinese Medical Association, Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.

    中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
    [7]
    Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on antiviral therapy for HBV/HCV-related hepatocellular carcinoma: A 2021 update[J]. J Clin Hepatol, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.

    中华医学会肝病学分会肝癌学组. HBV/HCV相关肝细胞癌抗病毒治疗专家共识(2021年更新版)[J]. 临床肝胆病杂志, 2021, 37(10): 2292-2302. DOI: 10.3969/j.issn.1001-5256.2021.10.008.
    [8]
    YANG J, RAO HY. EASL recommendations on treatment of hepatitis C: Final update of the series (2020)[J]. J Clin Hepatol, 2020, 36(12): 2681-2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009.

    杨甲, 饶慧瑛. 2020年欧洲肝病学会推荐意见: 丙型肝炎的治疗(最终更新版)[J]. 临床肝胆病杂志, 2020, 36(12): 2681-2687. DOI: 10.3969/j.issn.1001-5256.2020.12.009.
    [9]
    WEI L, LIM SG, XIE Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(2): 127-134. DOI: 10.1016/S2468-1253(18)30343-1.
    [10]
    ZHOU Q, YANG LH, JIANG FQ. Long-term prognosis of patients with hepatitis C virus-related hepatocellular carcinoma receiving direct-acting antiviral: A Meta-analysis[J]. J Clin Hepatol, 2021, 37(8): 1836-1840. DOI: 10.3969/j.issn.1001-5256.2021.08.018.

    周荃, 杨丽晖, 蒋芳清. 直接抗病毒药物改善HCV相关肝细胞癌患者远期预后效果的Meta分析[J]. 临床肝胆病杂志, 2021, 37(8): 1836-1840. DOI: 10.3969/j.issn.1001-5256.2021.08.018.
    [11]
    GAO Y, YANG J, SUN F, et al. Prevalence of anti-HCV antibody among the general population in mainland China between 1991 and 2015: A systematic review and meta-analysis[J]. Open Forum Infect Dis, 2019, 6(3): ofz040. DOI: 10.1093/ofid/ofz040.
    [12]
    CALVARUSO V, PETTA S, CRAXÌ A. Is global elimination of HCV realistic?[J]. Liver Int, 2018, 38(Suppl 1): 40-46. DOI: 10.1111/liv.13668.
    [13]
    DORE GJ, BAJIS S. Hepatitis C virus elimination: laying the foundation for achieving 2030 targets[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(2): 91-92. DOI: 10.1038/s41575-020-00392-3.
    [14]
    CHEN LN, JIN LZ, SUN LB, et al. Survey and analysis of HCV antibody positivity among 802 community-dwelling adults in Yanbian Prefecture, Jilin Province, China[J]. Chronic Pathematol J, 2013, 14(6): 463-464. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201306023.htm

    陈龙男, 金龙洙, 孙鲁白, 等. 吉林省延边州802名社区居民HCV抗体阳性率调查分析[J]. 慢性病学杂志, 2013, 14(6): 463-464. https://www.cnki.com.cn/Article/CJFDTOTAL-YYSO201306023.htm
    [15]
    LITAKER JR, TAMEZ N, LOPEZ BRAY C, et al. Hepatitis C antibody screening among baby boomers by a community-based health insurance company[J]. Popul Health Manag, 2021, 24(4): 492-495. DOI: 10.1089/pop.2020.0214.
    [16]
    MOORMAN AC, DROBENUIC J, KAMILI S. Prevalence of false-positive hepatitis C antibody results, National Health and Nutrition Examination Study (NHANES) 2007-2012[J]. J Clin Virol, 2017, 89: 1-4. DOI: 10.1016/j.jcv.2017.01.007.
    [17]
    CUI FQ, ZHUANG H. Progress in prevention and control of viral hepatitis since the establishing of the People's Republic of China[J]. Chin J Hepatol, 2021, 29(8): 725-731. DOI: 10.3760/cma.j.cn501113-20210722-00351.

    崔富强, 庄辉. 中国建国以来防控病毒性肝炎工作进展[J]. 中华肝脏病杂志, 2021, 29(8): 725-731. DOI: 10.3760/cma.j.cn501113-20210722-00351.
    [18]
    TRICKEY A, SOOD A, MIDHA V, et al. Clustering of hepatitis C virus antibody positivity within households and communities in Punjab, India[J]. Epidemiol Infect, 2019, 147: e283. DOI: 10.1017/S0950268819001705.
    [19]
    XU HM, KONG YM. Mother-infant relationship in chronic hepatitis B and chronic hepatitis C[J]. Chin J Pract Pediatr, 2010, 25(12): 912-915. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201012010.htm

    许红梅, 孔元梅. 慢性乙型肝炎和慢性丙型肝炎的母婴传播[J]. 中国实用儿科杂志, 2010, 25(12): 912-915. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSEK201012010.htm
    [20]
    GAO YH, LIU XE, ZHUANG H. Research progress on hepatitis C in children[J]. Chin J Viral Dis, 2016, 6(4): 300-306. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201604015.htm

    高玉华, 刘学恩, 庄辉. 儿童丙型肝炎研究进展[J]. 中国病毒病杂志, 2016, 6(4): 300-306. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201604015.htm
    [21]
    MIAO N, JIN LZ, PIAO HX, et al. Study on risk factors of hepatitis C virus infection in Yanbian Korean Prefecture Chinese[J]. Chin J Vaccines Immun, 2013, 19(2): 159-163. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201302019.htm

    缪宁, 金龙洙, 朴红心, 等. 延边朝鲜族自治州丙型肝炎病毒感染危险因素研究[J]. 中国疫苗和免疫, 2013, 19(2): 159-163. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM201302019.htm
    [22]
    PIAO HJ, ZHANG YZ, CHEN N, et al. Comparative study of risk factors for HCV infection between Korean-Chinese and Han nationality in Yanbian area[J]. J Med Sci Yanbian Univ, 2015, 38(4): 333-336. DOI: 10.16068/j.1000-1824.2015.04.035.

    朴海今, 张英哲, 陈宁, 等. 延边地区朝鲜族与汉族丙型肝炎病毒感染危险因素比较研究[J]. 延边大学医学学报, 2015, 38(4): 333-336. DOI: 10.16068/j.1000-1824.2015.04.035.
    [23]
    PIAO HX, YANG AT, SUN YM, et al. Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China[J]. PLoS One, 2014, 9(1): e86190. DOI: 10.1371/journal.pone.0086190.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (445) PDF downloads(44) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return